Abstract: Sleep apnea is treated by administering a therapeutically effective amount of 2-isopropyl-2,8-bis(3,4-dimethoxyphenyl)-6-methyl-6-azaoctane nitrile to a subject.
Abstract: A pharmaceutical preparation, which has an anti-hypertensive and cardio-protective effect, which coprises a pharmaceutically effective amount of a combination of .alpha.-isopropyl-.alpha.-[(N-methyl-N-homoveratryl)-.gamma.-aminopropyl]- 3,4-dimethoxyphenyl-acetonitrile in the form of pharmacologically acceptable acid addition salt, 2,4,7-triamino-6-phenyl-pteridine and 6-chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide as acitve ingredients, in combination with a carrier and auxiliary materials in single dosage form.
Type:
Grant
Filed:
September 30, 1988
Date of Patent:
September 10, 1991
Assignee:
Rohm-Pharma GmbH
Inventors:
Klaus Lossnitzer, Karl-Friedrich Ober, Gerhard Giebenhain, Gerhard Zeiss, Karl-Dieter Volger
Abstract: The present invention is directed to a pharmaceutical preparation for external or transdermal application which comprises a dispersion of liposomes, wherein said liposomes incorporate or enclose an active ingredient.
Abstract: The invention relates to pharmaceutical materials for local and non-irritating therapy for psoriasis, containing antipsoriatic ingredients. The pharmaceutical material is a liquid preparation of film-forming polymers and antipsoriatic ingredients, with which the psoriasis affected skin area can be covered and treated in situ with a medicated film or foil formed at the treatment site. Dithranol and/or glucocorticoid in combination with keratolytically acting urea are preferred for use as antipsoriatic ingredients.
Abstract: A diuretically active pharmacological composition which comprises 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid (furosemide) together with at least one compound of formula (I) ##STR1## wherein R is a hydrophilic radical, capable of increasing the water solubility of the resulting compound together with a suitable pharmacological carrier.
Abstract: What is disclosed is a method for the treatment of Parkinsonism or of psychic disturbances in a patient suffering therefrom, which method comprises orally or parenterally administering to said patient an effective amount of an active agent selected from the group consisting of (+)-trans-2-phenylcyclopropyl amine and physiologically acceptable acid addition salts thereof, said agent being essentially free of the corresponding (-)-enantiomer and its salts.
Abstract: Pharmaceutical compositions having a diuretic effect and containing as the active ingredient a compound of the formula ##STR1## wherein R is hydrogen, a pharmaceutically acceptable cation, methyl, or a hydrophilic group R', are disclosed, as are novel compounds wherein R is R'.This application is a continuation-in-part of application Ser. No. 860,824 filed Dec. 15, 1977, now abandoned.
Type:
Grant
Filed:
July 11, 1978
Date of Patent:
February 24, 1981
Assignee:
Rohm Pharma GmbH
Inventors:
Heinrich Knauf, Ernst Mutschler, Karl-Dieter Voelger
Abstract: A cardio-protective pharmaceutical composition is disclosed, which composition comprises an inert carrier and a pharmaceutically-effective amount of a combination of 2,4,7-triamino-6-phenyl-pteridine (triamterene) and a calcium antagonist, such as .alpha.-isopropyl-.alpha.-[(N-methyl-N-homoveratryl)-.gamma.-aminopropyl]- 3,4-dimethoxyphenyl-acetonitrile-hydrochloride (verapamil).
Type:
Grant
Filed:
December 19, 1977
Date of Patent:
June 5, 1979
Assignee:
Rohm Pharma GmbH
Inventors:
Albrecht Fleckenstein, Johanna Janke, Klaus Lossnitzer, Karl-Dieter Voelger